Acadia Pharmaceuticals, Inc. (ACAD) Tops Q3 EPS by 5c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $21.09 -1.4%
EPS Growth %: -62.5%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: -62.5%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.04), $0.05 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $1.9 million.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
